RegeneRx Biopharmaceuticals, Inc. announced that it has received a Notice of Acceptance for a patent from the Australian Patent Office for the use of Thymosin beta 4 (Tß4), the active pharmaceutical ingredient in the RegeneRx's proprietary drug candidate, RGN-352, to myelinate damaged neurons or axons (brain nerve cells). Myelination is a process of forming a myelin sheath around a nerve to allow nerve impulses to move more efficiently and is vitally important to healthy central nervous system functioning. The patent expiry is March 26, 2030, not including any potential extensions.